16.12.2022 | Tracker

Product Launch Tracker: HCPs discuss first drug to delay type 1 diabetes and the approval of world’s most expensive treatment

By Paul Cranston

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout November 2022 we tracked the global conversations of 1,811 HCPs who posted 2,465 English-language Twitter posts about the launches and approvals of new products.

Over the month of November, HCPs discussed and spread the news of several new product approvals, including a new treatment option for multiple myeloma, a gene therapy treatment for haemophilia B, and most notably, the approval of the first ever treatment to delay the onset of type 1 diabetes.

The news of the FDA approval of Provention Bio and Sanofi’s Tzield (teplizumab-mzwv) gained significant attention from HCPs online, with over 150 HCPs mentioning the new treatment in November. This approval was considered particularly important as it is the first ever treatment to delay the onset of type 1 diabetes. HCPs described the treatment as groundbreaking and highlighted the significance of the product as the 1st drug to alter the course of type 1 diabetes in 100 years; however, there was some concern over the cost of the treatment and that its impact is limited to an average delay of onset of roughly 2 years.

Earlier in the month some HCPs had also shared the news of Pfizer’s elranatamab gaining breakthrough therapy designation from the FDA as a treatment for relapsed and refractory multiple myeloma. HCPs congratulated Pfizer on the approval, celebrating it as great news, as well as reflecting on the developments in multiple myeloma treatment in the 21st century. They highlighted that 15 new drugs have been approved in the last 20 years, vastly increasing the number of treatment options available.

The other approval which gained notable attention from HCPs in November, was the FDA approval of the first gene therapy treatment for patients with haemophilia B. Hemgenix (etranacogene dezaparvovec-drlb), which is licenced by CSL gained attention from HCPs for being an innovative and “paradigm shifting” treatment. Others however expressed surprise at the cost of the treatment, with it also holding claim to being the world’s most expensive treatment.

The three most shared links from HCPs discussing product launches in June were:


Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 November and 30 November 2022, there were 2,465 HCP mentions of new pharmaceutical product launches and drug approvals from 1,811 unique HCP authors from around the world. 

Click here to the read the latest Product Launch Tracker

View all articles >

Meet the Author

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Suggested next

29.09.2020 | Article

Partnership opportunities between the NHS and UK Pharma

How the NHS and the pharmaceutical industry are collaborating during the COVID-19 pandemic

By Anni Neumann

05.07.2022 | Article

Product Launch Tracker: HCPs discuss approvals including for the prevention of smallpox and monkeypox.

HCPs also held around the approval of treatments for monkeypox

By Paul Cranston and Tomi Shobande

View all articles >